
Molecular Cancer Therapeutics p. 805 - 818 (2017)
Update date:2022-08-16
Topics:
Humphries-Bickley, Tessa
Castillo-Pichardo, Linette
Hernandez-O'Farrill, Eliud
Borrero-Garcia, Luis D.
Forestier-Roman, Ingrid
Gerena, Yamil
Blanco, Manuel
Rivera-Robles, Michael J.
Rodriguez-Medina, José R.
Cubano, Luis A.
Vlaar, Cornelis P.
Dharmawardhane, Suranganie
The Rho GTPases Rac (Ras-related C3 botulinum toxin substrate) and Cdc42 (cell division control protein 42 homolog) regulate cell functions governing cancer malignancy, including cell polarity, migration, and cell-cycle progression. Accordingly, our recently developed Rac inhibitor EHop-016 (IC50, 1,100 nmol/L) inhibits cancer cell migration and viability and reduces tumor growth, metastasis, and angiogenesis in vivo. Herein, we describe MBQ-167, which inhibits Rac and Cdc42 with IC50 values of 103 and 78 nmol/L, respectively, in metastatic breast cancer cells. Consequently, MBQ-167 significantly decreases Rac and Cdc42 downstream effector p21- activated kinase (PAK) signaling and the activity of STAT3, without affecting Rho, MAPK, or Akt activities. MBQ-167 also inhibits breast cancer cell migration, viability, and mammosphere formation. Moreover, MBQ-167 affects cancer cells that have undergone epithelial-to-mesenchymal transition by a loss of cell polarity and inhibition of cell surface actin-based extensions to ultimately result in detachment from the substratum. Prolonged incubation (120 hours) in MBQ-167 decreases metastatic cancer cell viability with a GI50 of approximately 130 nmol/L, without affecting noncancer mammary epithelial cells. The loss in cancer cell viability is due to MBQ-167- mediated G2-M cell-cycle arrest and subsequent apoptosis, especially of the detached cells. In vivo, MBQ-167 inhibits mammary tumor growth and metastasis in immunocompromised mice by approximately 90%. In conclusion, MBQ-167 is 10× more potent than other currently available Rac/Cdc42 inhibitors and has the potential to be developed as an anticancer drug, as well as a dual inhibitory probe for the study of Rac and Cdc42.
Shanghai Hongbang Medical Technology CO.,. Ltd
Contact:13671516988 /18917636693
Address:Room1, No67 Building, Yongde Road369, Wujing Town, Minhang Districy, Shanghai CIty, China.
Xiamen Kaijia Imp & Exp Co., Ltd.
Contact:86-592-5101177
Address:Room406 Luhui Building No. 65 Haitian Road Huli Xiamen,China.
Beijing Zhongshuo Pharmaceutical T & D Co.,Ltd
Contact:0086-10-64430626
Address:ea No 16, HEPINGLI,DONGCHENG DISTRICT,BEIJING,P.R.CHINA.
ShangHai BMG Chemical Co., Ltd
Contact:+86-13524845543
Address:Room 602, no 291 sikai road shanghai
Shanghai Science Peptide Biological Technology Co.,ltd
website:http://www.scipeptide.com
Contact:+86-21-51099675
Address:No.8 Changyang Rd
Doi:10.1007/BF00564334
()Doi:10.1016/j.ica.2016.05.055
(2016)Doi:10.1039/c4cc05020g
(2014)Doi:10.1016/j.molcatb.2014.08.022
(2014)Doi:10.1002/adsc.201901035
(2019)Doi:10.1021/acs.orglett.9b00283
(2019)